Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paltusotine in Carcinoid Syndrome
NCT05361668Phase 2Completed
- Sponsor
- Crinetics Pharmaceuticals
- Start
- Apr 2022
- Primary completion
- Mar 2024
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 2, randomised, open-label trial of paltusotine in Carcinoid Syndrome (CS) (2 arms), sponsored by Crinetics Pharmaceuticals. Primary endpoint: Incidence of Treatment-emergent Adverse Events at 8 weeks. Started Apr 2022; status: completed.
02
Drugs
paltusotine
03
Conditions
Carcinoid Syndrome (CS)
Beyond the preview
Go deeper on NCT05361668.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05361668.